The “Chronic Obstructive Pulmonary Disease Treatment Drug Industry Forecast” looks at past sales and reviews total world Chronic Obstructive Pulmonary Disease Treatment Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected Chronic Obstructive Pulmonary Disease Treatment Drug sales for 2023 through 2029. With Chronic Obstructive Pulmonary Disease Treatment Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Chronic Obstructive Pulmonary Disease Treatment Drug industry.
This Insight Report provides a comprehensive analysis of the global Chronic Obstructive Pulmonary Disease Treatment Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Chronic Obstructive Pulmonary Disease Treatment Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Chronic Obstructive Pulmonary Disease Treatment Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Chronic Obstructive Pulmonary Disease Treatment Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Chronic Obstructive Pulmonary Disease Treatment Drug.
The global Chronic Obstructive Pulmonary Disease Treatment Drug market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Chronic Obstructive Pulmonary Disease Treatment Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Chronic Obstructive Pulmonary Disease Treatment Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Chronic Obstructive Pulmonary Disease Treatment Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Chronic Obstructive Pulmonary Disease Treatment Drug players cover GSK, Novartis, Merck, Abbott, Boehringer Ingelheim, AstraZeneca, Roche, Teva and Vectura, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Chronic Obstructive Pulmonary Disease Treatment Drug market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Bronchodilators
PDE-4 Inhibitors
Steroids
Others
Segmentation by application
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
GSK
Novartis
Merck
Abbott
Boehringer Ingelheim
AstraZeneca
Roche
Teva
Vectura
Pfizer
Mylan
Allergan
Cipla
Akorn
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Chronic Obstructive Pulmonary Disease Treatment Drug Market Size 2018-2029
2.1.2 Chronic Obstructive Pulmonary Disease Treatment Drug Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Chronic Obstructive Pulmonary Disease Treatment Drug Segment by Type
2.2.1 Bronchodilators
2.2.2 PDE-4 Inhibitors
2.2.3 Steroids
2.2.4 Others
2.3 Chronic Obstructive Pulmonary Disease Treatment Drug Market Size by Type
2.3.1 Chronic Obstructive Pulmonary Disease Treatment Drug Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Chronic Obstructive Pulmonary Disease Treatment Drug Market Size Market Share by Type (2018-2023)
2.4 Chronic Obstructive Pulmonary Disease Treatment Drug Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Chronic Obstructive Pulmonary Disease Treatment Drug Market Size by Application
2.5.1 Chronic Obstructive Pulmonary Disease Treatment Drug Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Chronic Obstructive Pulmonary Disease Treatment Drug Market Size Market Share by Application (2018-2023)
3 Chronic Obstructive Pulmonary Disease Treatment Drug Market Size by Player
3.1 Chronic Obstructive Pulmonary Disease Treatment Drug Market Size Market Share by Players
3.1.1 Global Chronic Obstructive Pulmonary Disease Treatment Drug Revenue by Players (2018-2023)
3.1.2 Global Chronic Obstructive Pulmonary Disease Treatment Drug Revenue Market Share by Players (2018-2023)
3.2 Global Chronic Obstructive Pulmonary Disease Treatment Drug Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Chronic Obstructive Pulmonary Disease Treatment Drug by Regions
4.1 Chronic Obstructive Pulmonary Disease Treatment Drug Market Size by Regions (2018-2023)
4.2 Americas Chronic Obstructive Pulmonary Disease Treatment Drug Market Size Growth (2018-2023)
4.3 APAC Chronic Obstructive Pulmonary Disease Treatment Drug Market Size Growth (2018-2023)
4.4 Europe Chronic Obstructive Pulmonary Disease Treatment Drug Market Size Growth (2018-2023)
4.5 Middle East & Africa Chronic Obstructive Pulmonary Disease Treatment Drug Market Size Growth (2018-2023)
5 Americas
5.1 Americas Chronic Obstructive Pulmonary Disease Treatment Drug Market Size by Country (2018-2023)
5.2 Americas Chronic Obstructive Pulmonary Disease Treatment Drug Market Size by Type (2018-2023)
5.3 Americas Chronic Obstructive Pulmonary Disease Treatment Drug Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Chronic Obstructive Pulmonary Disease Treatment Drug Market Size by Region (2018-2023)
6.2 APAC Chronic Obstructive Pulmonary Disease Treatment Drug Market Size by Type (2018-2023)
6.3 APAC Chronic Obstructive Pulmonary Disease Treatment Drug Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Chronic Obstructive Pulmonary Disease Treatment Drug by Country (2018-2023)
7.2 Europe Chronic Obstructive Pulmonary Disease Treatment Drug Market Size by Type (2018-2023)
7.3 Europe Chronic Obstructive Pulmonary Disease Treatment Drug Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Chronic Obstructive Pulmonary Disease Treatment Drug by Region (2018-2023)
8.2 Middle East & Africa Chronic Obstructive Pulmonary Disease Treatment Drug Market Size by Type (2018-2023)
8.3 Middle East & Africa Chronic Obstructive Pulmonary Disease Treatment Drug Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Chronic Obstructive Pulmonary Disease Treatment Drug Market Forecast
10.1 Global Chronic Obstructive Pulmonary Disease Treatment Drug Forecast by Regions (2024-2029)
10.1.1 Global Chronic Obstructive Pulmonary Disease Treatment Drug Forecast by Regions (2024-2029)
10.1.2 Americas Chronic Obstructive Pulmonary Disease Treatment Drug Forecast
10.1.3 APAC Chronic Obstructive Pulmonary Disease Treatment Drug Forecast
10.1.4 Europe Chronic Obstructive Pulmonary Disease Treatment Drug Forecast
10.1.5 Middle East & Africa Chronic Obstructive Pulmonary Disease Treatment Drug Forecast
10.2 Americas Chronic Obstructive Pulmonary Disease Treatment Drug Forecast by Country (2024-2029)
10.2.1 United States Chronic Obstructive Pulmonary Disease Treatment Drug Market Forecast
10.2.2 Canada Chronic Obstructive Pulmonary Disease Treatment Drug Market Forecast
10.2.3 Mexico Chronic Obstructive Pulmonary Disease Treatment Drug Market Forecast
10.2.4 Brazil Chronic Obstructive Pulmonary Disease Treatment Drug Market Forecast
10.3 APAC Chronic Obstructive Pulmonary Disease Treatment Drug Forecast by Region (2024-2029)
10.3.1 China Chronic Obstructive Pulmonary Disease Treatment Drug Market Forecast
10.3.2 Japan Chronic Obstructive Pulmonary Disease Treatment Drug Market Forecast
10.3.3 Korea Chronic Obstructive Pulmonary Disease Treatment Drug Market Forecast
10.3.4 Southeast Asia Chronic Obstructive Pulmonary Disease Treatment Drug Market Forecast
10.3.5 India Chronic Obstructive Pulmonary Disease Treatment Drug Market Forecast
10.3.6 Australia Chronic Obstructive Pulmonary Disease Treatment Drug Market Forecast
10.4 Europe Chronic Obstructive Pulmonary Disease Treatment Drug Forecast by Country (2024-2029)
10.4.1 Germany Chronic Obstructive Pulmonary Disease Treatment Drug Market Forecast
10.4.2 France Chronic Obstructive Pulmonary Disease Treatment Drug Market Forecast
10.4.3 UK Chronic Obstructive Pulmonary Disease Treatment Drug Market Forecast
10.4.4 Italy Chronic Obstructive Pulmonary Disease Treatment Drug Market Forecast
10.4.5 Russia Chronic Obstructive Pulmonary Disease Treatment Drug Market Forecast
10.5 Middle East & Africa Chronic Obstructive Pulmonary Disease Treatment Drug Forecast by Region (2024-2029)
10.5.1 Egypt Chronic Obstructive Pulmonary Disease Treatment Drug Market Forecast
10.5.2 South Africa Chronic Obstructive Pulmonary Disease Treatment Drug Market Forecast
10.5.3 Israel Chronic Obstructive Pulmonary Disease Treatment Drug Market Forecast
10.5.4 Turkey Chronic Obstructive Pulmonary Disease Treatment Drug Market Forecast
10.5.5 GCC Countries Chronic Obstructive Pulmonary Disease Treatment Drug Market Forecast
10.6 Global Chronic Obstructive Pulmonary Disease Treatment Drug Forecast by Type (2024-2029)
10.7 Global Chronic Obstructive Pulmonary Disease Treatment Drug Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 GSK
11.1.1 GSK Company Information
11.1.2 GSK Chronic Obstructive Pulmonary Disease Treatment Drug Product Offered
11.1.3 GSK Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 GSK Main Business Overview
11.1.5 GSK Latest Developments
11.2 Novartis
11.2.1 Novartis Company Information
11.2.2 Novartis Chronic Obstructive Pulmonary Disease Treatment Drug Product Offered
11.2.3 Novartis Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Novartis Main Business Overview
11.2.5 Novartis Latest Developments
11.3 Merck
11.3.1 Merck Company Information
11.3.2 Merck Chronic Obstructive Pulmonary Disease Treatment Drug Product Offered
11.3.3 Merck Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Merck Main Business Overview
11.3.5 Merck Latest Developments
11.4 Abbott
11.4.1 Abbott Company Information
11.4.2 Abbott Chronic Obstructive Pulmonary Disease Treatment Drug Product Offered
11.4.3 Abbott Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Abbott Main Business Overview
11.4.5 Abbott Latest Developments
11.5 Boehringer Ingelheim
11.5.1 Boehringer Ingelheim Company Information
11.5.2 Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Treatment Drug Product Offered
11.5.3 Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Boehringer Ingelheim Main Business Overview
11.5.5 Boehringer Ingelheim Latest Developments
11.6 AstraZeneca
11.6.1 AstraZeneca Company Information
11.6.2 AstraZeneca Chronic Obstructive Pulmonary Disease Treatment Drug Product Offered
11.6.3 AstraZeneca Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 AstraZeneca Main Business Overview
11.6.5 AstraZeneca Latest Developments
11.7 Roche
11.7.1 Roche Company Information
11.7.2 Roche Chronic Obstructive Pulmonary Disease Treatment Drug Product Offered
11.7.3 Roche Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Roche Main Business Overview
11.7.5 Roche Latest Developments
11.8 Teva
11.8.1 Teva Company Information
11.8.2 Teva Chronic Obstructive Pulmonary Disease Treatment Drug Product Offered
11.8.3 Teva Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Teva Main Business Overview
11.8.5 Teva Latest Developments
11.9 Vectura
11.9.1 Vectura Company Information
11.9.2 Vectura Chronic Obstructive Pulmonary Disease Treatment Drug Product Offered
11.9.3 Vectura Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Vectura Main Business Overview
11.9.5 Vectura Latest Developments
11.10 Pfizer
11.10.1 Pfizer Company Information
11.10.2 Pfizer Chronic Obstructive Pulmonary Disease Treatment Drug Product Offered
11.10.3 Pfizer Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Pfizer Main Business Overview
11.10.5 Pfizer Latest Developments
11.11 Mylan
11.11.1 Mylan Company Information
11.11.2 Mylan Chronic Obstructive Pulmonary Disease Treatment Drug Product Offered
11.11.3 Mylan Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Mylan Main Business Overview
11.11.5 Mylan Latest Developments
11.12 Allergan
11.12.1 Allergan Company Information
11.12.2 Allergan Chronic Obstructive Pulmonary Disease Treatment Drug Product Offered
11.12.3 Allergan Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Allergan Main Business Overview
11.12.5 Allergan Latest Developments
11.13 Cipla
11.13.1 Cipla Company Information
11.13.2 Cipla Chronic Obstructive Pulmonary Disease Treatment Drug Product Offered
11.13.3 Cipla Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 Cipla Main Business Overview
11.13.5 Cipla Latest Developments
11.14 Akorn
11.14.1 Akorn Company Information
11.14.2 Akorn Chronic Obstructive Pulmonary Disease Treatment Drug Product Offered
11.14.3 Akorn Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, Gross Margin and Market Share (2018-2023)
11.14.4 Akorn Main Business Overview
11.14.5 Akorn Latest Developments
12 Research Findings and Conclusion
*If Applicable.